KR20090087094A - Iap 억제제 및 flt3 억제제의 조합물 - Google Patents

Iap 억제제 및 flt3 억제제의 조합물 Download PDF

Info

Publication number
KR20090087094A
KR20090087094A KR1020097013350A KR20097013350A KR20090087094A KR 20090087094 A KR20090087094 A KR 20090087094A KR 1020097013350 A KR1020097013350 A KR 1020097013350A KR 20097013350 A KR20097013350 A KR 20097013350A KR 20090087094 A KR20090087094 A KR 20090087094A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
substituted
cycloalkyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097013350A
Other languages
English (en)
Korean (ko)
Inventor
제임스 더글라스 그리핀
레이 자웰
Original Assignee
노파르티스 아게
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 다나-파버 캔서 인스티튜트 인크. filed Critical 노파르티스 아게
Publication of KR20090087094A publication Critical patent/KR20090087094A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097013350A 2006-11-28 2007-11-27 Iap 억제제 및 flt3 억제제의 조합물 Abandoned KR20090087094A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US60/867,448 2006-11-28
US89108807P 2007-02-22 2007-02-22
US60/891,088 2007-02-22

Publications (1)

Publication Number Publication Date
KR20090087094A true KR20090087094A (ko) 2009-08-14

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097013350A Abandoned KR20090087094A (ko) 2006-11-28 2007-11-27 Iap 억제제 및 flt3 억제제의 조합물

Country Status (20)

Country Link
US (1) US8492429B2 (cg-RX-API-DMAC7.html)
EP (1) EP2089024B1 (cg-RX-API-DMAC7.html)
JP (1) JP5394249B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090087094A (cg-RX-API-DMAC7.html)
AT (1) ATE509629T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007325280B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719543A2 (cg-RX-API-DMAC7.html)
CA (1) CA2670498A1 (cg-RX-API-DMAC7.html)
CO (1) CO6210722A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP099472A (cg-RX-API-DMAC7.html)
GT (1) GT200900142A (cg-RX-API-DMAC7.html)
IL (1) IL198551A0 (cg-RX-API-DMAC7.html)
MA (1) MA30966B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009005621A (cg-RX-API-DMAC7.html)
NO (1) NO20092417L (cg-RX-API-DMAC7.html)
PL (1) PL2089024T3 (cg-RX-API-DMAC7.html)
PT (1) PT2089024E (cg-RX-API-DMAC7.html)
RU (1) RU2456983C2 (cg-RX-API-DMAC7.html)
TN (1) TN2009000206A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008067280A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant))
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL2253614T3 (pl) * 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
US20090005411A1 (en) 2005-12-20 2009-01-01 Novartic Ag Combinations of Organic Compounds
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
CO6210722A2 (es) 2010-10-20
JP5394249B2 (ja) 2014-01-22
RU2456983C2 (ru) 2012-07-27
TN2009000206A1 (en) 2010-10-18
JP2010511059A (ja) 2010-04-08
PT2089024E (pt) 2011-08-31
US20100056467A1 (en) 2010-03-04
PL2089024T3 (pl) 2011-10-31
ATE509629T1 (de) 2011-06-15
EP2089024A2 (en) 2009-08-19
BRPI0719543A2 (pt) 2014-02-25
WO2008067280A2 (en) 2008-06-05
RU2009124590A (ru) 2011-01-10
WO2008067280A3 (en) 2008-08-07
NO20092417L (no) 2009-08-25
IL198551A0 (en) 2010-02-17
AU2007325280B2 (en) 2011-03-10
ECSP099472A (es) 2009-10-30
MA30966B1 (fr) 2009-12-01
AU2007325280A1 (en) 2008-06-05
MX2009005621A (es) 2009-06-12
CA2670498A1 (en) 2008-06-05
US8492429B2 (en) 2013-07-23
EP2089024B1 (en) 2011-05-18
GT200900142A (es) 2010-06-24

Similar Documents

Publication Publication Date Title
US8492429B2 (en) Combination of IAP inhibitors and FLT3 inhibitors
KR20090083412A (ko) 급성 골수성 백혈병의 치료를 위한 iap 억제제의 용도
CA2889717A1 (en) Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
JP7577672B2 (ja) Flt3阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
KR20070074552A (ko) 포스포디에스테라아제 5 억제제(pde5)와 조합한엔도텔린 a 수용체 (eta)길항제 및 이의 용도
JP2007530705A (ja) トリシリビン及び関連化合物による、腫瘍及び癌の有効な治療
KR20210003789A (ko) 림프종을 치료하는 방법
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
WO2017037587A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
WO2022094435A1 (en) Modulators of orphan nuclear receptors for treating pancreatitis, glioblastoma, sarcopenia and stroke
WO2012078416A2 (en) Monophosphate prodrugs of dapd and analogs thereof
KR20080038298A (ko) 아미노피리미딘 조절제 및 파네실 전이 효소 억제제를이용하는 flt3 키나아제의 상승적 조절
KR20080038297A (ko) 아미노피리미딘 키나아제 조절제를 사용한 flt3키나아제의 상승적 조절
CN113490497A (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
EP2249844A1 (en) Active substance combination with gemcitabine for the treatment of epithelial cancer
ES2549327T3 (es) Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis
von Mehren New therapeutic strategies for soft tissue sarcomas
CN101588801B (zh) Iap抑制剂和flt3抑制剂的组合
AU2005279344B2 (en) Use of midostaurin for treating gastrointestinal stromal tumors
TWI918772B (zh) 使用4-胺基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基環丙基)-6-(3-嗎啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-甲醯胺來治療腫瘤的方法
WO2025012029A1 (en) Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent
HK40111044A (en) Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment of acute myeloid leukemia
Ghias 8-Amino-adenosine and induction of apoptosis in multiple myeloma: Effect of novel purine analog on cellular signaling pathways

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131231

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141126

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee